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IgA nephropathy (IgAN), the most common primary
glomerulonephritis worldwide, has significant morbidity and
mortality as 20–40% of patients progress to end-stage renal
disease within 20 years of onset. In order to gain insight into
the molecular mechanisms involved in the progression of
IgAN, we systematically evaluated renal biopsies from such
patients. This showed that the MAPK/ERK signaling pathway
was activated in the mesangium of patients presenting with
over 1g/day proteinuria and elevated blood pressure, but
absent in biopsy specimens of patients with IgAN and
modest proteinuria (o1g/day). ERK activation was not
associated with elevated galactose-deficient IgA1 or IgG
specific for galactose-deficient IgA1 in the serum. In human
mesangial cells in vitro, ERK activation through mesangial
IgA1 receptor (CD71) controlled pro-inflammatory cytokine
secretion and was induced by large-molecular-mass IgA1-
containing circulating immune complexes purified from
patient sera. Moreover, IgA1-dependent ERK activation
required renin–angiotensin system as its blockade was
efficient in reducing proteinuria in those patients exhibiting
substantial mesangial activation of ERK. Thus, ERK activation
alters mesangial cell–podocyte crosstalk, leading to renal
dysfunction in IgAN. Assessment of MAPK/ERK activation in
diagnostic renal biopsies may predict the therapeutic efficacy
of renin–angiotensin system blockers in IgAN.
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IgA nephropathy (IgAN), also known as Berger’s disease, is
characterized by the deposition of IgA1-containing immune
complexes in the glomerular mesangium.1,2 This condition,
initially thought to be benign, is now recognized as a major
health problem because 20 to 40% of patients progress to end-
stage renal disease (ESRD) within 20 years after disease onset.3
Impaired kidney function is frequently associated with a
rise in blood pressure, which is, by itself, a risk factor for
chronic kidney disease.4 Substantial proteinuria is also a
recognized risk factor for chronic kidney disease progres-
sion,5 and magnitude of proteinuria combined with the
estimated glomerular filtration rate (eGFR) permits assess-
ment of risk for progression toward ESRD.6
Mesangial cells participate in the regulation of glomerular
hemodynamics and are critical for renal glomerular function.
These contractile cells fulfill multiple functions, including the
secretion of extracellular matrix proteins, growth factors and
cytokines, and the uptake of macromolecules and immune
complexes.7,8 In this context, change in the physiology of
mesangial cells seems to be an early event in progressive
glomerular injury, leading to modified composition of
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extracellular matrix and glomerular sclerotic changes.9 How-
ever, little is known about the molecular pathways involved in
altered physiology of mesangial cells during IgAN progression.
We have previously identified the transferrin receptor 1
(TfR1/CD71) as an IgA1 receptor and shown that IgA1
glycosylation and size (both altered in IgAN patients) are
essential for IgA1 binding to TfR1.10 In vitro stimulation of
human mesangial cells (HMCs) by high-molecular-mass
IgA1 induces TfR1 expression, which initiates a positive
feedback loop that could increase IgA1 mesangial deposition.11
Herein we describe molecular mechanisms triggered by
mesangial IgA1 deposition involved in IgAN progression. An
immunohistochemical evaluation of renal biopsies revealed a
correlation between IgA1-induced renal injury (that is, high
proteinuria and increased blood pressure) and mesangial
activation of the mitogen-activated protein kinase/extracel-
lular signal–regulated kinase (MAPK/ERK) pathway. This
pathway was involved in secretion of inflammatory cytokines
by HMCs activated by patients’ large-molecular-mass
IgA1-containing immune complexes (800–900 kDa). MAPK/
ERK activation did not correlate with serum galactose (Gal)-
deficient IgA1 levels (which are elevated in IgAN patients),
suggesting that aberrant O-glycan composition is not
sufficient for IgAN progression. Finally, our data showed
that renin–angiotensin system (RAS) was involved in IgA1-
dependent HMC activation. Patients with mesangial MAPK/
ERK activation responded with a significant decrease in
proteinuria when treated with RAS blockers (angiotensin-
converting enzyme (ACE) inhibitor or angiotensin II type 1
receptor blocker (ARB)). This observation supports the
notion that IgA1-dependent mesangial cell activation inter-
acts with downstream pathways following RAS activation.
Altogether, these results suggest that MAPK/ERK activation
alters the mesangial cell–podocyte crosstalk, leading to renal
dysfunction in IgAN. Our data also indicated that MAPK/
ERK activation may serve as new biomarker of IgAN that can
predict responsiveness to RAS blockers in IgAN patients.
RESULTS
The MAPK/ERK pathway is activated in mesangial areas of
renal biopsy specimens from IgAN patients with proteinuria
(41g/day) and elevated blood pressure
To characterize the molecular mechanisms involved in IgAN
progression, we first identified signaling pathways activated
in the mesangial cells. The MAPK/ERK signaling pathway
plays a critical role in the regulation of cell proliferation,
hypertrophy, cytokine secretion, and extracellular matrix
synthesis.12 ERK includes two highly homologous kinases,
denoted as ERK1 (p44, MAPK3) and ERK2 (p42, MAPK1).
Immunohistochemical analysis of phospho (p)-ERK1/
2(Thr202/Tyr204) (p-ERK1/2) expression in remnant renal
biopsy specimens from IgAN patients revealed two distinct
patterns, depending on the magnitude of proteinuria: in the
tissues from patients excreting 41 g/day, p-ERK1/2 expres-
sion was found in 420% of mesangial cells and in
glomerular endothelial cells and/or podocytes in more than
half of the glomeruli (Figure 1a). This pattern clearly differed
from that observed in tissues from IgAN patients with
modest proteinuria (o1 g/day) and tissues from healthy
subjects undergoing donor nephrectomy that showed
different degrees of podocyte and endothelial cells positivity
but only few mesangial cells with the staining (o20% of
stained cells; Figure 1a). In all biopsy specimens, collecting
ducts were stained, as previously described.13 Staining with
an isotype-control immunoglobulin did not show mesangial
staining (Figure 1a). In mesangial and glomerular endothelial
cells, p-ERK1/2 was observed mostly in the nucleus, which
was observed less frequently in patients with modest
proteinuria. Further comparative analysis using a semiquan-
titative mesangial score of p-ERK1/2 staining further
confirmed its correlation with proteinuria (Figure 1b and
c). Podocyte and endothelial cell score (independently of
mesangial cell score) did not correlate with proteinuria
(Supplementary Figure S1 online). Mesangial p-ERK1/2
expression was also associated with high mean blood pressure
(MBP; Figure 1d and e). Other parameters such as age,
hematuria, eGFRMDRD (eGFR using the Modification of Diet
in Renal Disease equation), or gender were not associated
with p-ERK1/2 staining (Figure 1f–i and Table 1). The strong
correlation between proteinuria and MBP (r¼ 0.5514;
P¼ 0.0006) did not allow analysis of a possible independent
contribution of p-ERK1/2 to each of these parameters
(Supplementary Figure S2 online). An association between
MAPK/ERK activation and proteinuria was also observed
when patients treated with RAS blockers at the time of
diagnostic biopsy were excluded from the analysis (Supple-
mentary Figure S3 online). Thus, IgAN patients with
41 g/day proteinuria and elevated blood pressure had
activated MAPK/ERK in the mesangium, mostly in nuclei.
Because phosphorylated ERK is known to translocate to the
nucleus of cells where it can phosphorylate and regulate a
number of transcription factors,14 these observations provide
a link between mesangial cell activation and functional
alteration of glomeruli in IgAN.
MAPK/ERK pathway activation does not correlate with
pathology variables included in the Oxford classification
The lesions observed in renal biopsy specimens from IgAN
patients have been recently classified in the Oxford
classification.15 In this classification, four major pathology
variables are evaluated in the MEST score that includes
mesangial proliferation (M), endocapillary proliferation (E),
glomerulosclerosis (S), and tubular atrophy and interstitial
fibrosis (T). Mesangial hypercellularity, segmental glomer-
ulosclerosis, and tubular atrophy/interstitial fibrosis were
associated with a worse prognosis (50% decrease in eGFR or
ESRD achieved within 5 years of follow-up) independently of
clinical assessment.15 We performed analyses to determine
whether p-ERK1/2 expression correlates with parameters
based on the Oxford classification MEST score. The results
revealed that p-ERK1/2 staining was not associated with any
of the four variables (Figure 2).
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MAPK/ERK pathway is not activated in renal mesangium
in biopsy specimens from non-IgAN proteinuric
glomerulonephritis patients
To further evaluate the significance of the correlation between
mesangial p-ERK1/2 and proteinuria, we investigated
p-ERK1/2 staining pattern in renal biopsy specimens from
patients with other forms of glomerulonephritis (membran-
ous glomerulonephritis or systemic lupus erythematosus
nephritis; n¼ 6). In renal biopsy specimens from proteinuric
membranous glomerulonephritis patients, the pattern of
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p-ERK1/2 labeling was similar to that found for IgAN
patients with modest proteinuria, whereas MAPK/ERK
pathway was activated in the mesangium of systemic lupus
erythematosus patients (Figure 3). IgA deposits were present
in the mesangia of all systemic lupus erythematosus patients,
including the one with quiescent disease. Therefore, protein-
uria by itself does not induce mesangial activation of MAPK/
ERK pathway.
MAPK/ERK pathway activation is not associated with serum
levels of Gal-deficient IgA1
IgAN is an immune complex–mediated glomerulonephritis
characterized by increased levels of Gal-deficient IgA1
in the circulation and glomerular deposits.16,17 We there-
fore explored a possible link between abnormal IgA1
O-glycosylation (evaluated by lectin enzyme-linked immu-
nosorbent assay (ELISA), as previously described18–20) and
mesangial ERK1/2 phosphorylation. As expected, IgAN
patients had elevated serum levels of Gal-deficient IgA1
compared with that for healthy controls (Figure 4a).
However, there was no difference in the serum levels of
Gal-deficient IgA1 between IgAN patients with and without
mesangial p-ERK1/2 staining, even after neuraminidase
treatment of purified serum IgA1 to remove terminal sialic
acid (Figure 4a and b). Gal-deficient IgA1 neo-antigens
present in the serum of IgAN patients are recognized by
circulating glycan-specific immunoglobulin G (IgG).21
Therefore, we compared the levels of IgG specific for Gal-
deficient IgA1 between patients with and without mesangial
activation of MAPK/ERK pathway. The results showed that
serum levels of IgG antibodies and IgG/IgA1 complexes did
not differ between these two groups of patients, although the
differences between IgAN patients and healthy controls were
significant (Figure 4c and d). Therefore, circulating levels of
Gal-deficient IgA1, IgA1/IgG complexes, and IgG antibodies
specific for Gal-deficient IgA1 did not discriminate the
mesangial activation of ERK in IgAN patients’ renal biopsy
specimens. This finding suggests that additional factors are
involved in IgAN progression.21,22
Table 1 | Clinical data
Group
Low (o1.1) p-ERK1/2
mesangial staining
High (41.1) p-ERK1/2
mesangial staining
Number 15 20
Age (years) 38.53 (23–69) 37.10 (20–77)
Gender ratio (M/F) 9/6 16/4
MBP (mmHg)* 95.1 (65.7–120.0) 105.2 (81.0–133.3)
Proteinuria (g/day)*** 1.66 (0.53–7.12) 3.67 (1.32–8.00)
Hematuria ( 105 RBC/ml) 2.4 (0–10) 103 (0–104)
eGFRMDRD 62.8 (12–114) 72.7 (8–287)
CKD stage (1/2/3/4/5) 4/3/6/1/1 5/5/5/2/3
RAS blockers (w/wo) 4/11 4/16
M0/M1 0/15 3/17
E0/E1 5/10 8/12
S0/S1 6/9 5/15
T0/T1/T2 8/4/3 10/5/5
Follow-up interval (months) 22.3 (0–76) 25.3 (0–91)
Abbreviations: CKD, chronic kidney disease; eGFRMDRD, estimated glomerular
filtration rate using the Modification of Diet in Renal Disease equation; F, female;
M, male; MBP, mean blood pressure; p-ERK1/2, phosphorylated extracellular
signal–regulated kinases 1 and 2; RAS, renin–angiotensin system; RBC, red blood
cell; w/wo, with/without.
*Po0.05, ***Po0.001. Numbers are expressed as mean (range) for continuous data
or number of patients for discontinuous ones.
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Figure 2 |Mitogen-activated protein kinase/extracellular
signal–regulated kinase (MAPK/ERK) pathway of mesangial
activation is not associated with histological variables of the
MEST (mesangial proliferation (M), endocapillary proliferation
(E), glomerulosclerosis (S), and tubular atrophy and
interstitial fibrosis (T)) score from the Oxford Classification.
Distribution of (a) mesangial proliferation (M0/M1), (b)
endocapillary proliferation (E0/E1), (c) glomerulosclerosis (S0/S1),
and (d) tubular atrophy and interstitial fibrosis (T0/T1/T2) scores in
IgA nephropathy (IgAN) patients presenting low or high
mesangial score for phosphorylated extracellular signal–regulated
kinases 1 and 2 (p-ERK1/2) labeling. ns, not significant.
Figure 1 |Mesangial activation of mitogen-activated protein kinase/extracellular signal–regulated kinase (MAPK/ERK) pathway
correlates with increased proteinuria and mean blood pressure (MBP). (a) Immunostaining of phosphorylated extracellular
signal–regulated kinases 1 and 2 (p-ERK1/2) in renal biopsy specimens from IgA nephropathy (IgAN) patients and healthy controls. Patients
were divided into two groups according to the p-ERK1/2 mesangial score (lowo1.1 and high41.1). (b) Proteinuria in patients presenting a
high or low mesangial score for p-ERK1/2 staining. (c) Correlation between p-ERK1/2 mesangial staining score and proteinuria. (d) MBP
distribution in patients presenting a high or low mesangial score for p-ERK1/2 staining. (e) Correlation between p-ERK1/2 mesangial staining
score and MBP. (f) Age distribution in patients presenting a high or low mesangial score for p-ERK1/2 staining. ns, not significant.
(g) Hematuria in patients presenting a high or low mesangial score for p-ERK1/2 staining. (h) eGFRMDRD (estimated glomerular filtration rate
using the Modification of Diet in Renal Disease equation) values in patients presenting a high or low mesangial score for p-ERK1/2 staining.
(i) Gender distribution (males in filled histograms and females in open histograms) in patients presenting a high or low mesangial score for
p-ERK1/2 staining. F, female; M, male. All data are mean±s.e.m. *Po0.05, ***Po0.001. ns, not significant.
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Pathogenic circulating macromolecular IgA1 complexes
activate MAPK/ERK pathway activation
Factors that could be involved in mesangial activation of
MAPK/ERK are high-molecular-mass circulating IgA1-con-
taining immune complexes (IgA1-CICs).23 Larger complexes
(800–900 kDa) stimulate proliferation of cultured HMCs,
whereas smaller complexes (700–800 kDa) inhibit prolifera-
tion.24 In contrast, uncomplexed IgA1 does not affect cellular
proliferation.24 Therefore, we evaluated the capacity of IgA1-
CICs from serum of an IgAN patient and Gal-deficient IgA1
purified from the plasma of a patient with multiple myeloma
(IgA1 Mce) to stimulate ERK activation in cultured HMCs. As
shown in Figure 5a, phosphorylation of ERK1/2 was intense
in HMCs after addition of high-molecular-mass stimulatory
CIC (IgA1-CIC-S, molecular mass 4800 kDa) and was
observed to a lesser degree with small-molecular-mass
inhibitory CIC (IgA1-CIC-I, molecular mass o800 kDa) or
with uncomplexed IgA1. In time-course studies, ERK1/2 was
rapidly phosphorylated after incubation of HMCs with a
high-molecular-mass Gal-deficient IgA1 myeloma protein
(pIgA1 Dou) previously shown to induce HMC activation11
as well as after incubation with platelet-derived growth factor
(PDGF)-BB (Figure 5b and c; used as a positive control).
These data strongly suggest that the mesangial p-ERK1/2 in
proteinuric IgAN patients results directly from mesangial cell
activation by deposited IgA1 complexes.
Another pathway important for cellular proliferation is
the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/
mammalian target of rapamycin (mTOR) pathway. MAPK/
ERK and PI3K/Akt/mTOR are the major pathways involved
in cellular proliferation, but their downstream effectors can
differ.25 We assessed the induction of Akt phosphorylation on
Ser473 (p-Akt) following HMC stimulation. In pIgA1 (Dou)-
stimulated HMCs, Akt was phosphorylated in a time-
dependent manner and preincubation of HMCs with
wortmannin (a specific inhibitor of PI3K) blocked Akt
phosphorylation (Figure 5b). Phosphorylation of mTOR, one
of the major downstream effectors of PI3K/Akt pathway,26
was induced by mesangial cell activation and rapamycin (a
pharmacological inhibitor of mTOR) blocked mTOR activa-
tion (Figure 5b and c). FKHRL1, a signaling molecule
downstream of the PI3K/Akt pathway, is involved in the
regulation of cellular proliferation.27 IgA1-CIC-S purified
from serum of an IgAN patient increased FKHRL1
Systemic lupus
erythematosus nephritis
Membranous
glomerulonephritis
Figure 3 |Mesangial activation of mitogen-activated protein kinase/extracellular signal–regulated kinase (MAPK/ERK) pathway in
other proteinuric glomerulonephritis. Immunostaining of phosphorylated extracellular signal–regulated kinases 1 and 2
(p-ERK1/2) in renal biopsy tissues from patients with systemic lupus erythematosus nephritis or membranous glomerulonephritis (MGN)
showing that proteinuria can be observed without p-ERK1/2 expression in mesangial cells in patients with MGN.
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Figure 4 |Activation of the mitogen-activated protein kinase/
extracellular signal–regulated kinase (MAPK/ERK) pathway in
mesangial cells is not associated with serum levels of
aberrantly glycosylated IgA1, IgG/IgA immune complex, or
anti-Gal-deficient-IgA1 IgG antibodies. (a) Serum levels of
galactose (Gal)-deficient IgA1 (evaluated by enzyme-linked
immunosorbent assay (ELISA) using Helix aspersa agglutinin HAA
lectin) (before and after neuraminidase treatment) in healthy
subjects, in all IgA nephropathy (IgAN) patients, and in IgAN
patients presenting high or low levels of phosphorylated
extracellular signal–regulated kinases 1 and 2
(p-ERK1/2) mesangial score. OD, optical density. Right panel,
detection of Gal-deficient IgA1 following neuraminidase
treatment. (b, c) Detection of IgG-gA1 complexes and IgG anti-
Gal-deficient IgA1 in the serum of patients presenting a high or
low p-ERK1/2 mesangial score. *Po0.05; ***Po0.001.
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phosphorylation to a greater extent than did IgA1-CIC-I or
uncomplexed polymeric IgA1 (Mce) (Figure 5d). Thus, the
MAPK/ERK and PI3K/Akt/mTOR pathways are induced after
HMC stimulation by IgA1-CICs from IgAN patients.
MAPK/ERK and PI3K/Akt/m-TOR pathways are involved in
IL-6 secretion and HMC proliferation, respectively
We and others have shown that HMC activation by pIgA1
(Dou) leads to cellular proliferation and release of the pro-
inflammatory cytokine interleukin-6 (IL-6) from these
cells.11,28 Therefore, we examined involvement of the
MAPK/ERK and PI3K/Akt/mTOR signaling pathways in
these HMC responses. HMCs were preincubated with or
without pharmacological inhibitors, stimulated with pIgA1
(Dou), and cellular proliferation was analyzed. Preincubation
with either wortmannin or rapamycin blocked pIgA1-
induced cellular proliferation (Figure 6a), whereas PD98059
(ERK1/2 inhibitor) had no significant effect (Figure 6a).
In contrast, inhibition of ERK kinases reduced IL-6
secretion from HMCs stimulated with pIgA1 (Dou)
(Figure 6b). An opposite effect (that is, an increased IL-6
secretion) was observed in wortmannin- or rapamycin-
treated cells (Figure 6b). These results revealed that the
stimulation of HMC proliferation by high-molecular-mass
pIgA1 depends on the PI3K/Akt/FKHRL1 pathway but not
on the MAPK/ERK pathway. In contrast, the MAPK/ERK
pathway activated in HMCs stimulated by high-molecular-
mass IgA1 is mainly involved in pro-inflammatory cytokine
secretion.
The pIgA1-induced HMC activation is dependent on TfR1
signaling
TfR1/CD71 was previously identified as an IgA1 receptor and
its role in IgAN pathogenesis has been characterized.10 TfR1
is overexpressed and colocalized with deposited IgA1 in
patients’ renal biopsy specimens.29 After exploring the
biochemical pathways involved in IgA1-induced HMC
activation, we assessed the possible involvement of TfR1 in
IgA1-induced stimulation of these pathways in HMCs. We
have previously characterized a monoclonal antibody (mAb)
A24 specific for TfR1 that targets proliferating cells, blocks
cellular division, and induces cellular apoptosis.30,31 Pre-
incubation of HMCs with mAb A24 blocked pIgA1 (Dou)-
induced IL-6 secretion (Figure 7a) as well as cellular
proliferation (Figure 7b). Based on these results, we conclude
that the PI3K/Akt/mTOR and the ERK1/2 pathways leading
to HMC proliferation and cytokine secretion involve TfR1
engagement by pIgA1.
This conclusion was further examined by preincubation of
the cells with the TfR1 ectodomain (sTfR1). This treatment
completely abrogated IgA1-dependent signaling in HMCs
(Figure 7c). In contrast, PDGF-BB-induced Akt phosphor-
ylation was not blocked by sTfR1 (Figure 7d). Therefore,
pIgA1-induced signaling in HMCs likely involves TfR1.
pIgA1 but not other TfR1 ligands promote calcium signaling
in mesangial cells
In vitro stimulation of HMCs by pIgA1 myeloma protein
(IgA1 Dou) or by purified IgA1 from IgAN patients induced
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Figure 5 |Activation of human mesangial cells (HMCs) by pIgA1 induced mitogen-activated protein kinase/extracellular
signal–regulated kinase (MAPK/ERK) and phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR)
signaling pathways. (a) Circulating immune complexes (CICs) from an IgA nephropathy (IgAN) patient and uncomplexed pIgA1 myeloma
protein activate MAPK/ERK1/2 pathway in HMCs. Serum-starved HMCs were stimulated for 15min with platelet-derived growth factor
(PDGF)-BB, IgA1-containing CICs from an IgAN patient (CIC-S, large-molecular-mass stimulatory CIC; CIC-I, small-molecular-mass inhibitory
CIC), and uncomplexed naturally Gal-deficient pIgA1 myeloma protein (pIgA1 Mce, IgA1). Cell lysates were immunoblotted with anti-p-
ERK1/2 and re-probed for actin as control for equal protein loading. NS, nonstimulated. (b, c) Time-course stimulation of HMCs with pIgA1
and PDGF-BB. Serum-starved HMCs were treated with or without 1 mmol/l wortmannin (W) or 25 nmol/l rapamycin (R) for 30min and then
activated with (b) pIgA1 (Dou) (pIgA1) or (c) PDGF-BB for the indicated lengths of time. Cell lysates were immunoblotted with anti-p-Akt,
anti-p-mTOR, and anti-p-ERK1/2 antibodies as described in the Materials and Methods section. Anti-ERK1/2 antibody was used as control for
equal protein loading. Data are representative of at least three independent experiments. (d) CICs from an IgAN patient and uncomplexed
pIgA1 myeloma protein activated Akt1/FKHRL1 pathway in HMCs. Serum-starved HMCs were stimulated for 15 or 60min with PDGF-BB,
IgA1-containing CICs from an IgAN patient (CIC-S and CIC-I), and uncomplexed Gal-deficient pIgA1 myeloma protein (pIgA1 Mce, IgA1). Cell
lysates were immunoblotted with anti-p-FKHRL1 antibodies (p-FKHRL1) and re-probed with actin as control for equal protein loading.
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TfR1 expression and initiated a positive feedback loop
promoting increased mesangial IgA1 deposition.11 In con-
trast, the other TfR1 ligands induced a decrease in receptor
expression. Therefore, we compared the ability of TfR1
ligands, that is, pIgA1 (Dou), Apo-Tf, and Fe-Tf, to induce
signaling in mesangial cells. Because calcium mobilization is a
common event involved in cell activation by most receptors,
we evaluated calcium signaling as a marker of HMC
activation by these ligands. pIgA1 was the only TfR1 ligand
that induced calcium mobilization in serum-starved HMCs
(Figure 8). PDGF-BB, as the positive control, also induced
calcium mobilization. Therefore, in growth-arrested HMCs,
pIgA1 was the only TfR1 ligand that induced HMC signaling.
pIgA1-induced mesangial cell activation involves the RAS
Treatments simultaneously targeting high blood pressure and
proteinuria often decrease the progression of chronic kidney
disease, thus delaying the onset of ESRD. One of the most
prevalent treatments of proteinuria is based on angiotensin II
blockade. Because IgA1-induced phosphorylation of mesan-
gial ERK1/2 was observed in patients with high blood
pressure and 41 g/day proteinuria, we examined the effect of
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Figure 6 |Activation of mitogen-activated protein kinase/
extracellular signal–regulated kinase (MAPK/ERK) and
phosphoinositide 3-kinase/protein kinase B/mammalian
target of rapamycin (PI3K/Akt/mTOR) signaling pathways are
involved in interleukin-6 (IL-6) secretion and human
mesangial cell (HMC) proliferation, respectively. (a) Activation
of PI3K/Akt/mTOR pathway regulates IgA1-dependent HMC
proliferation. Serum-starved HMCs were preincubated with
inhibitors of PI3 kinase (wortmannin; 1 mmol/l), mTOR (rapamycin;
25 nmol/l), or ERK (PD98059, 10 mmol/l) for 2 h and then activated
with pIgA1 (Dou; 0.5mg/ml) for another 48 h before an 18-h
incorporation of [3H]-thymidine. Nonstimulated (NS) HMCs served
as control. Data are representative of three independent
experiments (error bars, s.d.). *Po0.05, **Po0.01, ***Po0.001
(two-tailed t-test). ns, not significant. (b) Blocking of MAPK/ERK
pathway inhibits IL-6 secretion by pIgA1-stimulated HMCs. Serum-
starved HMCs were preincubated with inhibitors for 2 h and then
activated with or without pIgA1 (0.5mg/ml) overnight. NS HMCs
served as control. Supernatants were then collected and IL-6
secreted in cultures was quantified by enzyme-linked
immunosorbent assay (ELISA). Data are means±s.d. of three
independent experiments. *Po0.05, **Po0.01, ***Po0.001 (two-
tailed t-test).
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Figure 7 |pIgA1-dependent human mesangial cell (HMC)
stimulation is abrogated by transferrin receptor 1 (TfR1)
blocking. (a, b) The anti-TfR1 monoclonal antibody (mAb) A24
inhibited (a) interleukin-6 (IL-6) secretion and (b) cellular
proliferation in pIgA1-stimulated HMCs. HMCs were preincubated
for 2 h with mAb A24 (50 mg/ml) before activation with pIgA1
(1mg/ml). NS, nonstimulated. Cytokine secretion and cell
proliferation were assessed after overnight and 48-h incubation,
respectively, as described in the Materials and Methods section.
Data are the means±s.d. from three independent experiments.
*Po0.05, **Po0.01 (two-tailed t-test). (c) HMCs were pretreated
for 30min with wortmannin (W; 1mmol/l), rapamycin (R; 25 nmol/l),
or soluble TfR1 (sTfR, 200mg/ml) before stimulation with pIgA1
(0.5mg/ml) for 10min. Cell lysates were immunoblotted with anti-
p-Akt1 (p-Akt1) and equal loading of proteins was determined by
blotting with anti-Akt1 antibody. (d) Platelet-derived growth
factor (PDGF)-BB-dependent HMC stimulation was not abrogated
by soluble TfR1. HMCs were pretreated for 30min with
wortmannin (1 mmol/l), rapamycin (25 nmol/l), or soluble TfR1
(200 mg/ml) before stimulation with PDGF-BB (10 ng/ml) for
10min. Cell lysates were immunoblotted with anti-p-Akt1 (p-Akt1)
and equal loading of proteins was determined by blotting with
anti-Akt1 antibody.
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angiotensin II blockade on ERK1/2 phosphorylation induced
by pIgA1. As shown in Figure 9a, exposure of HMCs to
angiotensin II (100 nmol/l) induced ERK1/2 phosphorylation
to the same extent as did pIgA1 (Dou). Preincubation of the
cells with an angiotensin II type 1 receptor (AT1R) blocker,
losartan, inhibited this ERK1/2 phosphorylation in angio-
tensin II- and pIgA1-stimulated cells (Figure 9a). As a
consequence, losartan also blocked IL-6 secretion from the
cells (Figure 9b). Therefore, pIgA1-induced p-ERK1/2
activation is apparently dependent on AT1R activation and
blockade of this pathway thus provides a new rationale for
the use of RAS blockers in the treatment of IgAN.
Reduced proteinuria due to RAS blocker therapy is more
effective in IgAN patients with a high mesangial score for
MAPK/ERK activation
To further evaluate the pathological or clinical relevance of
the ability of RAS blockers to suppress MAPK/ERK activation
in mesangial cells, we tested whether the decrease in
proteinuria induced by RAS blocker therapy (ACE inhibitor
or angiotensin II type 1 receptor blocker) was associated with
the status of p-ERK1/2 mesangial score. Patients who were
not under RAS blocker therapy (ACE inhibitor or angio-
tensin II type 1 receptor blockers) at the time of biospy, scored
for mesangial expression of p-ERK1/2 and were given RAS
blocker therapy for at least 28 days32 thereafter were studied
for the progression of proteinuria. As shown in Figure 10a,
treatment reduced proteinuria to a greater degree in patients
who presented higher scores for MAPK/ERK activation at the
time of diagnosis. Interestingly, the efficacy of RAS blockers to
decrease MBP did not differ among patients presenting high
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Figure 9 |pIgA1-induced human mesangial cell (HMC)
activation is dependent on ATR1 signaling. Serum-starved
HMCs were preincubated with AT1R antagonist losartan (10mmol/l)
overnight and then activated overnight with or without pIgA1
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(a) The presence of phosphorylated extracellular signal–regulated
kinases 1 and 2 (p-ERK1/2) was examined by immunoblotting of
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Data are the mean±s.d. from three independent experiments.
*Po0.05, ***Po0.001; two-tailed t-test.
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or low levels of p-ERK1/2 activation (Figure 10b). Altogether,
these data suggest that the effect of RAS blockers in the control
of proteinuria may depend on mesangial MAPK/ERK
activation, whereas control of MBP would be independent
of this pathway. We conclude that immunostaining of renal
biopsy specimens for p-ERK1/2 at the time of diagnosis may
predict the efficacy of RAS blockers in proteinuric IgAN
patients. Further studies with large cohorts of patients are
necessary to validate these data in larger populations.
DISCUSSION
IgAN is characterized by IgA1-containing immune complex
deposits in the glomerular mesangium that are frequently
associated with a mesangial cell proliferation, mesangial matrix
expansion, and intraglomerular and interstitial infiltration of
inflammatory cells.33 Although several reports have addressed
the initial steps involved in the disease pathogenesis (such as
the characterization of IgA1 structural abnormalities and the
mechanisms underlying the formation of circulating IgA1
complexes),16,17,21,22 the molecular mechanisms involved in
disease progression are still unknown.
We aimed to identify molecular pathways involved in
IgAN progression. We screened a series of remnant renal
biopsy specimens from IgAN patients to identify these
molecular pathways. Our experiments revealed that activa-
tion of the MAPK/ERK pathway (identified by ERK1/2
phosphorylation) occurs in a subgroup of IgAN patients
presenting with high blood pressure and 41 g/day protei-
nuria, both clinical features frequently associated with disease
progression. More importantly, the mesangial MAPK/ERK
score correlated with the degree of decrease in proteinuria
induced by RAS blocker therapy. Further multicenter studies
with a large cohort of proteinuric IgAN patients will be
needed to validate the use of p-ERK1/2 immunostaining to
help predict the therapeutic efficacy.
A surprising observation in this study was that IgAN
patients with less proteinuria had no expression of mesangial
p-ERK1/2 in spite of bona fide IgA deposits in the
mesangium. Indeed, our in vitro data unequivocally demon-
strate that IgA1-containing immune complexes induce
ERK1/2 phosphorylation in HMCs. Additional parameters
therefore influence the response of mesangial cells in vivo.
Among these parameters, the genetic background would be a
prime candidate34–37 through expression of various, yet
unidentified, factors, whether inhibitory or
co-stimulatory. Identification of these factors could be a
major challenge for nephrologists for further progress in the
understanding this common renal disease.
MAPK/ERK signal transduction pathway is implicated in
several cellular functions, such as cytokine production, cell
survival, and inflammation.38–40 Masaki et al.13 have
previously investigated the status of MAPK/ERK activation
in renal tissue from a cohort of patients with various
glomerulopathies and showed a correlation between the
status of MAPK/ERK and cell proliferation. Unfortunately,
the absence of IgAN patients in this study precludes the
comparison with our data.
Our study revealed that IgA1-dependent stimulation of
HMCs induced a rapid phosphorylation of the major
molecular effectors of the MEK/ERK cascade (namely
ERK1/2), indicating that this pathway is activated in IgA1-
stimulated mesangial cells. The MEK/ERK inhibitor
PD098059 inhibited IgA1-induced IL-6 secretion by HMCs
but was less effective in blocking HMC proliferation. IL-6
itself can promote HMC activation.41 Because PD98059
has only a partial effect on HMC proliferation, we suggest
that IgA1-induced HMC proliferation is not dependent on
the autocrine secretion of IL-6. In different forms of
glomerulonephritis, kidney inflammation is controlled by
secretion of pro-inflammatory cytokines by both resident and
infiltrating cells.42–44 Several findings from animal models
indicate that the inflammation cascade can be triggered by
activation of resident kidney cells. Thus, activation of the
IgA1-induced MEK/ERK pathway in HMCs could be
important for the development of renal inflammation
triggered by pro-inflammatory cytokines in IgAN. This
postulate can be supported by the observation that in
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signal–regulated kinases 1 and 2 (p-ERK1/2) predicts decrease
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proteinuric IgAN patients p-ERK1/2 is observed in cell nuclei
where these factors could regulate gene expression involved
in inflammation. The crosstalk between the four different
known MAPK pathways in IgAN remains to be elucidated
and would provide important information on the inflam-
matory aspect of the pathogenesis of this disease.
Mesangial cells are located between glomerular capillaries
and are therefore in close proximity with other glomerular
cells (that is, endothelial cells and podocytes). Although
additional factors that influence IgAN progression remain to
be identified, our data show an association between
mesangial expression of p-ERK1/2 and alteration of the
filtration barrier (manifested by 41 g/day proteinuria),
suggesting a crosstalk between mesangial cells and podocytes.
This crosstalk may involve pro-inflammatory cytokines
produced by pIgA1-activated HMCs45 that would modulate
the glomerular filtration barrier, either directly or indirectly
through recruitment of inflammatory cells. Therefore, in
pathological conditions such as IgAN, mesangial MAPK/ERK
activation would lead to altered mesangial cell biology and to
the release of soluble factors that could induce podocyte
de-differentiation and podocyte loss. Further studies are
necessary to clarify the downstream target of MAPK/ERK
involved in the control of mesangial cell activation and
cytokine secretion by mesangial cells.
A strong candidate for such a downstream target is
nuclear factor (NF)-kB. Soluble IgA1 aggregates and
aberrantly glycosylated IgA1 induce NF-kB activation46 and
AT1R expression47 in cultured mesangial cells, suggesting a
crosstalk between these two systems. Interestingly, angioten-
sin is also able to directly promote NF-kB activation and IL-6
secretion.48 In addition, ACE inhibitors reduce macrophage
infiltration through the control of monocyte chemoattractant
protein-1 synthesis that may promote the development of
glomerulonephritis,49 providing additional evidence of im-
plication of NF-kB in glomerulonephritis.
We have previously identified the transferrin receptor
(TfR1 or CD71) as a new pIgA1 receptor and characterized
its implication in IgAN. Here we show that IgA1-dependent
HMC signaling is dependent on TfR engagement. In
addition, preincubation of HMCs with an anti-TfR antibody
(mAb A24) blocked IgA1-dependent mesangial cell function,
as evidenced by the blockade of IL-6 secretion and mesangial
cell proliferation. These results confirm that the pathways
leading to both cellular responses originate from TfR1
engagement by pIgA1. These findings also underscore the
critical requirement for identification of the first signaling
events after IgA1-dependent TfR1 engagement to control
HMC cell responses and disease progression. Interestingly, of
all the known TfR1 ligands, only pIgA1 was able to induce
cell activation as evidenced by calcium mobilization in
growth-arrested HMCs. The structural requirement to
achieve TfR1-induced HMC activation by pIgA1 is still
unknown. However, the multimeric nature of high-molecu-
lar-mass IgA1 that allows the formation of large TfR1
aggregates could be involved in this process.
Angiotensin II plays a central role as a mediator of
glomerular hemodynamic adaptation and injury. It has been
suggested that angiotensin II–induced mesangial cell con-
traction with efferent arteriolar vasoconstriction initiates
intraglomerular hypertension and may lead to enhanced
matrix formation and renal fibrosis after increased synthesis
of transforming growth factor-b.50 Several studies have
shown that ARBs are particularly effective in reducing
proteinuria through their direct action on AT1R-expressing
cells in endothelium and vascular smooth muscle expressing
the receptor.51,52 Therefore, blocking the renin–angiotensin–
aldosterone system would be beneficial beyond its effect on
blood pressure.52 For example, the glomerular efferent
arteriole is particularly sensitive to angiotensin II.53 There-
fore, ARBs would ease the excessive pressure in the
glomerular capillaries and, consequently, reduce proteinuria.
ARBs are especially efficacious in controlling proteinuria
in patients with glomerulonephritis associated with altera-
tions in mesangial cell function (such as diabetes and
IgAN).54,55 We show here that patients with a high mesangial
score for p-ERK1/2 activation at the time of diagnostic
biopsy had greater decrement in proteinuria after treatment.
These data suggest that glomerular MAPK/ERK activation
could be used to predict which IgAN patients will respond to
anti-proteinuric, RAS-suppression therapy. Altogether our
results suggest that MAPK/ERK activation controls the
crosstalk between mesangial cells and podocytes through
activation of AT1R. We propose a new molecular mechanism
by which AT1R would lead to proteinuria by controlling
MAPK/ERK activation in mesangial cells and crosstalk with
podocytes, slowing progression to ESRD. The link between
AT1R and TfR1 remains to be elucidated.
In summary, our experiments revealed a new molecular
mechanism in which MAPK/ERK activation controls the
crosstalk between mesangial cells and podocytes. We
postulate that blocking this activation pathway in mesangial
cells will prevent progression to ESRD in IgAN patients.
Moreover, we propose that activation of MAPK/ERK path-
way in the mesangium may serve as a biomarker for renal
injury. Treatment with ARBs and ACE inhibitors to dampen
this pathway may slow progression of IgAN to ESRD.
MATERIALS AND METHODS
Cells and chemical agents
HMCs were obtained from Lonza Verviers (SPRL, Belgium). Cells
were cultured at 37 1C in a humidified environment containing 5%
CO2 in RPMI 1640-Glutamax medium supplemented with 20%
fetal calf serum, 50 U/ml penicillin, 50 mg/ml streptomycin, and
insulin–transferrin–selenium-A (all from Invitrogen SARL, Cergy
Pontoise, France). Experiments were performed with cells using
passages 4 to 8. For Figure 5, HMCs were cultured.11,24 Human
naturally Gal-deficient IgA1 myeloma proteins (Dou) and (Mce)
were purified.56,57 Naturally Gal-deficient pIgA1 myeloma protein
(Mce) has been shown to mimic aberrantly glycosylated IgA1 in
IgAN patients,23,24,58,59 and the heterogeneity of its O-glycosylation
has been characterized by high-resolution mass spectrometry60,61 as
well as by the patterns of binding to selective lectins.20,62 Circulating
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IgA1-containing immune complexes from the serum of an IgAN
patient were purified by size-exclusion chromatography and pooled
as stimulatory or inhibitory complexes.24,63 This serum sample from
an IgAN patient was selected as a representative sample based on
medium to high serum levels of Gal-deficient IgA1 and the presence
of both stimulatory and inhibitory immune complexes.24,63 PDGF-
BB was purchased from Sigma (St Louis, MO). Monoclonal anti-
human TfR antibody (mAb A24) was produced and purified in our
laboratory.31 Wortmannin was obtained from Alexis Biochemicals
(Paris, France); rapamycin and PD98059 were purchased from
Calbiochem (Fontenay sous Bois, France). Soluble human TfR1
(kindly provided by P Bjorkman, CalTech, Pasadena, CA) was
expressed in a lytic baculovirus/insect cell expression system.64
ELISA
IL-6 production was determined by standard ELISA assay following
the manufacturer’s instructions (Human IL-6 DuoSet ELISA, R&D
Systems, Lille, France).
Stimulation of HMCs
HMCs were serum starved (arrested in G0 phase of the cell cycle)
before stimulation experiments. Briefly, HMC culture medium was
changed to RPMI 0.5% fetal calf serum and replaced at 48, 36, 24, and
4 h before the stimulation. Cells were stimulated with human naturally
Gal-deficient IgA1 myeloma proteins (Dou and Mce), circulating
IgA1-containing immune complexes from IgAN patients, or PDGF-
BB as indicated in figure legends. Chemical inhibitors (wortmannin,
PD98059, and rapamycin) or TfR blocking agents (A24 and sTfR)
were preincubated for 30 min before the stimulation.
HMCs were lysed in Lysis buffer (50 mmol/l N-(hydroxyethyl)-
piperazine-N’-2-ethanesulfonic acid (HEPES), 50 mmol/l NaF,
100 mmol/l NaCl, Triton-X-100 1%, SDS 0.1% supplemented with
protease inhibitors: leupeptin and aprotinin (Sigma-Aldrich, Saint-
Quentin Fallavier, France) at 2 mg/ml). After disruption with a
scraper, cell lysates were centrifuged at 4 1C at 12,000 r.p.m. for
15 min to pellet the cellular debris. Protein (supernatant) content
was measured using the Bio-Rad Protein assay (Bio-Rad, Hercules,
CA) and then denatured and reduced in Laemli sample buffer
(62 mmol/l Tris-HCl, pH 6.8, 10% b-mercaptoethanol, 10%
glycerol, 2% SDS) and boiled for 5 min. A total of 30 mg of proteins
was loaded on a 7.5% SDS-PAGE gel. In Figure 5, HMCs were lysed
using lysis buffer (50 mmol/l HEPES, 150 mmol/l NaCl, 1 mmol/l
EDTA, 2.5 mmol/l EGTA, 10% glycerol, 0.1% Tween-20, and
1 mmol/l DTT) supplemented with protease and phosphatase
inhibitor cocktails (Sigma).63 The protease inhibitor cocktail
contained 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride
(AEBSF), aprotinin, leupeptin, bestatin, pepstatin A, and E-64.
Phosphatase inhibitor cocktails included cantharidin, bromotetra-
misole, microcytin LR, sodium orthovanadate, sodium molybde-
nate, sodium tartarate, and imidazole. In addition, we used
phenylmethanesulfonyl fluoride (1 mmol/l), NaF (1 mmol/l), and
b-glycerophosphate (10 mmol/l) (Sigma). The resultant lysates were
separated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis using 10% polyacrylamide gel (Bio-Rad).
Proteins were transferred onto polyvinylidene difluoride mem-
brane (Millipore, Saint-Quentin en Yvelines, Belgium) and im-
munoblots were incubated with the following antibodies: anti-
phospho-mTOR (Ser 2448 residue), anti-phospho-Akt (Ser 473
residue), anti-phospho-ERK1/2 (the murine mAb reacts with ERK1
and ERK2 when dually phosphorylated at Thr202 and Tyr204 of
Erk1 (Thr185 and Tyr187 of Erk2), and singly phosphorylated at
Tyr204), and ERK1/2, Akt, and mTOR (all from Cell Signaling
Technology, Danvers, MA), followed by the appropriate secondary
antibody-horseradish peroxidase conjugate (Pierce, France) and
visualized by chemiluminescence with the ECL kit (Thermo
Scientific, Villebon sur Yvette, France).
Proliferation assay
HMCs were trypsinized, resuspended in RPMI-1640 with 0.5% fetal
calf serum, added in triplicate at the concentration of 1 104 cells
per well in 96-well tissue culture plates (Falcon, Oxnard, CA), and
starved for 48 h before experiments. Proliferation of quiescent
HMCs was induced using pIgA1 at 0.5 mg/ml or PDGF-BB at 50 ng/
ml for 24 h. For the inhibition experiments, mAb A24 (50 mg/ml),
wortmannin (1mmol/l), rapamycin (25 nmol/l), and PD98059
(10mmol/l) were added 2 h before addition of IgA1. Proliferation
was measured over 18 h, after pulses with 1 mCi/well [3H]thymidine
(Amersham Life Science, Buckinghamshire, UK). Cells were then
washed, trypsinized for 2 h at 37 1C, and harvested on filters with a
96-well Harvester (Pharmacia), and the incorporation of [3H]thy-
midine was measured with a b-plate microscintillation counter
(GE Healthcare, Aulnay sous Bois, France).
Analysis of O-glycosylation by lectin assay using Helix
aspersa agglutinin (HAA)
The glycan content of serum IgA1 and CIC-containing IgA1 was
tested by ELISA using HAA, a lectin that binds to terminal N-
acetylgalactosamine (GalNAc) residues.22 Briefly, microtitration
plates were coated overnight at 4 1C with 10 mg/ml of F(ab’)2
fragment of goat anti-human IgA in borate-buffered saline. The
wells were blocked with blocking buffer for 1 h at 37 1C. Serum
samples adjusted to 10 mg/ml of IgA1 and 500mg/ml of total
proteins, respectively, were added in duplicates in dilution buffer
overnight at 4 1C. Samples were treated or not for 3 h at 37 1C with
neuraminidase from Vibrio cholerae (Roche, Meylan, France) at
10 mU/ml in 50 mmol/l sodium acetate buffer with 4 mmol/l
calcium chloride and 10 mg/ml bovine serum albumin, pH¼ 5.5,
to allow desialylation of the captured IgA1. After washing, samples
were incubated for 3 h at 37 1C with biotinylated HAA diluted at 1/
500 in phosphate-buffered saline, 0.05% Tween-20, 1% bovine
serum albumin, and 0.1% sodium azide, pH 7.6. The bound
biotinylated HAA lectin was then detected with streptavidin-AP
(Sigma, Saint Quentin Fallavier, France) incubated for 30 min at
37 1C, followed by the addition of streptavidin-AP substrate (BD, Le
Pont de Claix, France) and by the reading of optical density at
405 nm. The lectin reactivity was expressed as optical density units.
IgG-IgA complexes and IgG anti-Gal-deficient IgA1 detection by
ELISA were performed as previously described.65 Briefly, for IgG-IgA
complexes, detection plates were coated with 10 mg/ml F(ab’)2
fragment of goat anti-human IgA (BD Biosciences, Le Pont-De-
Claix, France) and, after blocking, diluted sera containing equal
amounts of total IgA were then added to plates. Rabbit anti-human
IgG (Hþ L) AP conjugate (Clinisciences, Nanterre, France) was
used for the detection of IgA-IgG complexes. For detection of IgG
anti-Gal-deficient IgA1, plates were coated with 10 mg/ml of
desialylated and degalactosylated myeloma IgA.
Measurement of free intracellular calcium
Cells were loaded in glass-bottom microwell dishes (Matek Corpora-
tion, Ashland, MA) with 1mmol/l of Fura2-AM (Invitrogen) and
pluronic acid (F-127, Invitrogen) and incubated at 37 1C for 30 min.
Cells were then washed with Ringer’s solution (in mmol/l: 145 NaCl,
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5.4 KCl, 2 CaCl2, 1 MgCl2, 10 glucose, 10 HEPES, and 0.1% bovine
serum albumin, pH 7.5, with NaOH). For acquisition, cells were
excited by wavelengths of 340 and 380 nm. Fluorescence emission of
several cells was simultaneously recorded at a frequency of 1 Hz using
a dual-excitation fluorometric imaging system (TILL-Photonics,
Gra¨felfingen, Germany) controlled by TILL-Vision software. Signals
were computed as relative ratio units of the fluorescence intensity of
the different wavelengths (340/380 nm). For data analysis, individual
ratios were then analyzed using Origin 7.5 software (Integral Software,
Paris, France), normalizing the ratio values with first value ((F/
F0)1). Area under curve was calculated for each stimulation.
Patients’ renal tissues: immunohistochemistry and analysis
Renal biopsy specimens (n¼ 35) from patients with IgAN (defined
by the predominant mesangial deposition of IgA by immunofluor-
escence) were obtained from the Nephrology Department of Hoˆpital
Bichat-Claude Bernard, Paris, France. Biopsies were classified
according to the Oxford classification (which scores biopsy findings
according to the MEST score66). All biopsy specimens contained at
least 8 glomeruli available for scoring. Biopsy specimens with
480% of global glomerular sclerosis were excluded. Normal kidney
tissue specimens were obtained from living donor nephrectomy
kidneys before transplantation. All patients and controls signed an
informed consent document.
Immunohistochemistry was performed in 4 mm paraffin sections
using anti-p-ERK1/2 (Thr202/Tyr204) rabbit monoclonal antibodies
(no. 4370, Cell Signaling Technology). Semiquantitative mesangial
score for p-ERK1/2 staining was determined for each glomerulus (0:
absence of mesangial cell labeling, 1:o20% positive mesangial cells,
2: 20–50% positive mesangial cells, 3: 450% positive mesangial cells
stained positively) and the mean score for each patient was
considered as the patient’s p-ERK1/2 mesangial staining score.
Scoring was performed by two independent pathologists in a
blinded fashion. Glomeruli were analyzed at  400 magnification.
Statistical analyses
Differences in proteinuria, MBP, age, hematuria, eGFRMDRD, HAA
binding, IgA1/IgG complexes, and IgG anti-Gal-deficient IgA1
between IgAN patients with high and low mesangial MAPK/ERK
activation were analyzed through Mann–Whitney or unpaired t-test
with Welch’s correction depending on Gaussian distribution of
variables. MBP and proteinuria correlation with p-ERK1/2 mesan-
gial staining score were performed with nonparametric Spearman’s
correlation. Sex ratio, diagnosis repartition, and MEST score
repartition were analyzed with Fisher’s exact test or w2 when there
were X3 conditions. Increase of HAA binding to IgA1 after
neuraminidase treatment, and proteinuria, eGFRMDRD, and MBP
changes were analyzed through two-way analysis of variance for
repeated measures. Statistical analyses were performed using a two-
tailed t-test. Results are presented as mean±s.d. unless indicated
otherwise in figure legends. A P-value of o0.05 was considered
significant. All statistical analyses were performed with GraphPad
Prism version 5 (GraphPad Software, San Diego, CA).
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